Beranda › Amiloidosis › Tennessee
Uji klinis Amiloidosis di Tennessee
7 studi untuk Amiloidosis mencari peserta di lokasi di Tennessee.
Kota di Tennessee
Teks studi resmi (Bahasa Inggris)
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- Research Site, Germantown
- Research Site, Nashville
Menerima pesertaStudi observasional
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06465810TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
- Clinical Trial Site, Nashville
Menerima pesertaFase 3
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07223203DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
- Clinical Trial Site, Memphis
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07358078Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
- Vanderbilt Ingram Cancer Center, Nashville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT05145816A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
- University of Tennessee Graduate School of Medicine, Knoxville
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Jul 2026 · NCT05951816A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
- Research Site, Nashville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT07081646A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
- Vanderbilt University Medical Center. /ID# 273510, Nashville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Mei 2026 · NCT06158854Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.